{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:43:35Z","timestamp":1791380615434,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000204","name":"Vancouver Foundation","doi-asserted-by":"publisher","award":["FOI22-7100"],"award-info":[{"award-number":["FOI22-7100"]}],"id":[{"id":"10.13039\/501100000204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>People who use drugs (PWUD) and Indigenous-PWUD in rural and remote communities are met with considerable barriers in access to opioid agonist treatments (OAT) in comparison to their urban counterparts. OAT is met with low rates of uptake and retention owing to clinic policies limiting access to take-home doses. Digital technologies may improve access to OAT for PWUD in rural and remote communities. The objective of this study was to understand willingness to use an asynchronous witnessed-dosing phone application among rural and remote PWUD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Qualitative semi-structured interviews were conducted with PWUD in rural and small communities in British Colombia, Canada (n\u2009=\u200932). Participants had to be\u2009\u2265\u200919\u00a0years old and have been on a prescribed OAT program within the 1-year of when the study began. A content analysis was completed on interview transcripts based on categories identified by the research team.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants described access barriers to OAT medications, which was contingent upon housing-related factors. Regardless of living in town, in coastal communities, or on Tla\u2019amin Nation treaty lands, participants described accessing OAT medications as restricting, impractical, and stigmatizing. When presented with a potential alternative delivery method via an asynchronous virtual application, participants described potential improvements in not only access to their OAT medications, but overall quality of life through, independence and increased opportunities to engage in day-to-day activities. Participants noted potential difficulties in keeping mobile devices.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings help illustrate how current OAT prescribing practices and the challenges with requiring in-person witnessed doses for people living in rural and remote communities, exercising control over OAT patients, ultimately limiting the autonomy of PWUD. There is a clear need to implement virtual OAT programs to improve access to OAT medications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01302-z","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:01:07Z","timestamp":1759921267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The potential use of digital technologies to enhance opioid agonist treatment in rural and remote communities of British Columbia, Canada"],"prefix":"10.1186","volume":"22","author":[{"given":"Amreetha","family":"Jayathilake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Bardwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"1302_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13011-022-00463-5","volume":"17","author":"EM Pijl","year":"2022","unstructured":"Pijl EM, Alraja A, Duff E, Cooke C, Dash S, Nayak N, et al. Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review. Subst Abuse Treat Prev Policy. 2022;17:62.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1302_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12954-021-00585-2","volume":"19","author":"KM Scarfone","year":"2022","unstructured":"Scarfone KM, Maghsoudi N, McDonald K, Stefan C, Beriault DR, Wong E, et al. Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019\u2013April 2020. Harm Reduct J. 2022;19:3.","journal-title":"Harm Reduct J"},{"key":"1302_CR3","unstructured":"British Columbia Coroners Service. Unregulated Drug Deaths - Summary [Internet]. 2025. Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiNjhiYjgxYzUtYjIyOC00ZGQ2LThhMzEtOWU5Y2Q4YWI0OTc5IiwidCI6IjZmZGI1MjAwLTNkMGQtNGE4YS1iMDM2LWQzNjg1ZTM1OWFkYyJ9"},{"key":"1302_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1186\/s12889-022-14586-8","volume":"22","author":"K Hu","year":"2022","unstructured":"Hu K, Klinkenberg B, Gan WQ, Slaunwhite AK. Spatial-temporal trends in the risk of illicit drug toxicity death in British Columbia. BMC Public Health. 2022;22:2121.","journal-title":"BMC Public Health"},{"key":"1302_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102937","volume":"91","author":"A Owusu-Bempah","year":"2021","unstructured":"Owusu-Bempah A, Luscombe A. Race, cannabis and the Canadian war on drugs: an examination of cannabis arrest data by race in five cities. Int J Drug Policy. 2021;91: 102937.","journal-title":"Int J Drug Policy"},{"key":"1302_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105993","volume":"91","author":"ME Socias","year":"2020","unstructured":"Socias ME, Wood E, Dong H, Brar R, Bach P, Murphy SM, et al. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial. Contemp Clin Trials. 2020;91: 105993.","journal-title":"Contemp Clin Trials"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13011-019-0241-2","volume":"14","author":"G Bardwell","year":"2019","unstructured":"Bardwell G, Wood E, Brar R. Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Subst Abuse Treat Prev Policy. 2019;14:50.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1302_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13011-023-00525-2","volume":"18","author":"G Bardwell","year":"2023","unstructured":"Bardwell G, Bowles JM, Mansoor M, Werb D, Kerr T. Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study. Subst Abuse Treat Prev Policy. 2023;18:14.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1302_CR9","doi-asserted-by":"crossref","unstructured":"Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;m772.","DOI":"10.1136\/bmj.m772"},{"key":"1302_CR10","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.14947","volume":"115","author":"M Piske","year":"2020","unstructured":"Piske M, Zhou H, Min JE, Hongdilokkul N, Pearce LA, Homayra F, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction. 2020;115:1482\u201393.","journal-title":"Addiction"},{"key":"1302_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","volume":"74","author":"KC Priest","year":"2019","unstructured":"Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257\u201365.","journal-title":"Int J Drug Policy"},{"key":"1302_CR12","unstructured":"Parkin S. Chapter 2. habitus and drug using environments: health, place and live experience. Ashgate Publishing; 2013. pp. 15\u201331."},{"key":"1302_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12954-022-00725-2","volume":"19","author":"G Bardwell","year":"2022","unstructured":"Bardwell G, Mansoor M, Van Zwietering A, Cleveland E, Snell D, Kerr T. The \u201cgoldfish bowl\u201d: a qualitative study of the effects of heightened surveillance on people who use drugs in a rural and coastal Canadian setting. Harm Reduct J. 2022;19:136.","journal-title":"Harm Reduct J"},{"key":"1302_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.17269\/s41997-021-00504-9","volume":"112","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Lappalainen L. The need to prioritize research, policy, and practice to address the overdose epidemic in smaller settings in Canada. Can J Public Health. 2021;112:733\u20136.","journal-title":"Can J Public Health"},{"key":"1302_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108896","volume":"143","author":"KA Hallgren","year":"2022","unstructured":"Hallgren KA, Darnton J, Soth S, Blalock KL, Michaels A, Grekin P, et al. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. J Subst Abuse Treat. 2022;143: 108896.","journal-title":"J Subst Abuse Treat"},{"key":"1302_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.116683","volume":"345","author":"G Bardwell","year":"2024","unstructured":"Bardwell G, Ivsins A, Wallace JR, Mansoor M, Kerr T. \u201cThe machine doesn\u2019t judge\u201d: Counternarratives on surveillance among people accessing a safer opioid supply via biometric machines. Soc Sci Med. 2024;345: 116683.","journal-title":"Soc Sci Med"},{"key":"1302_CR17","doi-asserted-by":"publisher","first-page":"E986","DOI":"10.1503\/cmaj.201618","volume":"192","author":"M Tyndall","year":"2020","unstructured":"Tyndall M. A safer drug supply: a pragmatic and ethical response to the overdose crisis. CMAJ. 2020;192:E986\u20137.","journal-title":"CMAJ"},{"key":"1302_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13722-023-00372-3","volume":"18","author":"JB Darnton","year":"2023","unstructured":"Darnton JB, Bhatraju EP, Beima-Sofie K, Michaels A, Hallgren KA, Soth S, et al. \u201cSign Me Up\u201d: a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic. Addict Sci Clin Pract. 2023;18:21.","journal-title":"Addict Sci Clin Pract"},{"key":"1302_CR19","unstructured":"Menzies D, Elwood K. Chapter 5: Canadian Tuberculosis Standards 7th Edition: 2014 \u2013 Treatment of Tuberculosis disease [Internet]. Government of Canada. 2014. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition\/edition-17.html"},{"key":"1302_CR20","doi-asserted-by":"publisher","unstructured":"Ragheb S, White J, Jarand J, Fisher D, Lim R. Assessing patient satisfaction with Video-Observed Therapy (VOT) for drug-susceptible tuberculosis during the COVID-19 pandemic. Tuberculosis and non-tuberculous mycobacterial diseases [Internet]. European Respiratory Society; 2023 [cited 2024 Oct 9]. p. PA2802. Available from: http:\/\/erj.ersjournals.com\/lookup\/doi\/https:\/\/doi.org\/10.1183\/13993003.congress-2023.PA2802","DOI":"10.1183\/13993003.congress-2023.PA2802"},{"key":"1302_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209181","volume":"157","author":"M Giles","year":"2024","unstructured":"Giles M, Reynales L, Jayaraman A, Kaplan O, Verma K, Wiest K, et al. Usability and feasibility of a take-home methadone web-application for opioid treatment program patients: a small business innovation research mixed methods study. J Subst Use Addict Treat. 2024;157: 209181.","journal-title":"J Subst Use Addict Treat"},{"key":"1302_CR22","unstructured":"How It Works [Internet]. Sonara Health. [cited 2024 Jun 9]. Available from: https:\/\/www.sonarahealth.com\/how-it-works"},{"key":"1302_CR23","doi-asserted-by":"publisher","DOI":"10.1017\/9781108623568","volume-title":"Rapid ethnographies: a practical guide","author":"C Vindrola-Padros","year":"2020","unstructured":"Vindrola-Padros C. Rapid ethnographies: a practical guide. Cambridge; New York, NY: Cambridge University Press; 2020."},{"key":"1302_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/nhs.12048","volume":"15","author":"M Vaismoradi","year":"2013","unstructured":"Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15:398\u2013405.","journal-title":"Nurs Health Sci"},{"key":"1302_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11133-021-09500-4","volume":"44","author":"JA Reich","year":"2021","unstructured":"Reich JA. Power, positionality, and the ethic of care in qualitative research. Qual Sociol. 2021;44:575\u201381.","journal-title":"Qual Sociol"},{"key":"1302_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s42466-020-00059-z","volume":"2","author":"L Busetto","year":"2020","unstructured":"Busetto L, Wick W, Gumbinger C. How to use and assess qualitative research methods. Neurol Res Pract. 2020;2:14.","journal-title":"Neurol Res Pract"},{"key":"1302_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/08897077.2019.1680479","volume":"42","author":"VWL Tsang","year":"2021","unstructured":"Tsang VWL, Papamihali K, Crabtree A, Buxton JA. Acceptability of technological solutions for overdose monitoring: perspectives of people who use drugs. Subst Abuse. 2021;42:284\u201393.","journal-title":"Subst Abuse"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1503\/cmaj.221550","volume":"195","author":"G Bardwell","year":"2023","unstructured":"Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T. Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes. CMAJ. 2023;195:E668\u201376.","journal-title":"CMAJ"},{"key":"1302_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jsat.2011.12.008","volume":"43","author":"L Richardson","year":"2012","unstructured":"Richardson L, Wood E, Montaner J, Kerr T. Addiction treatment-related employment barriers: the impact of methadone maintenance. J Subst Abuse Treat. 2012;43:276\u201384.","journal-title":"J Subst Abuse Treat"},{"key":"1302_CR30","unstructured":"Clinical Respurces for Opioid Use Disorder [Internet]. Opioid Use Disorder. 2023. Available from: https:\/\/www.bccsu.ca\/opioid-use-disorder\/"},{"key":"1302_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/00914509221128598","volume":"50","author":"L Michaud","year":"2023","unstructured":"Michaud L, Van Der Meulen E, Guta A. Between care and control: examining surveillance practices in harm reduction. Contemp Drug Probl. 2023;50:3\u201324.","journal-title":"Contemp Drug Probl"},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1005574918294","volume":"24","author":"P Bourgois","year":"2000","unstructured":"Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24:165\u201395.","journal-title":"Cult Med Psychiatry"},{"key":"1302_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/cjrm.cjrm_56_23","volume":"29","author":"K Hodgson","year":"2024","unstructured":"Hodgson K, Bowles JM, Mansoor M, Rooke E, Bardwell G. \u2018I\u2019m on the coast and I\u2019m on methadone\u2019: a qualitative study examining access to opioid agonist treatment in rural and coastal British Columbia. Can J Rural Med. 2024;29:117\u201324.","journal-title":"Can J Rural Med"},{"key":"1302_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103200","volume":"94","author":"JM Bowles","year":"2021","unstructured":"Bowles JM, Smith LR, Mittal ML, Harding RW, Copulsky E, Hennessy G, et al. \u201cI wanted to close the chapter completely \u2026 and I feel like that [carrying naloxone] would keep it open a little bit\u201d: Refusal to carry naloxone among newly-abstinent opioid users and 12-step identity. Int J Drug Policy. 2021;94: 103200.","journal-title":"Int J Drug Policy"},{"key":"1302_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/14659891.2018.1523968","volume":"24","author":"P Wood","year":"2019","unstructured":"Wood P, Opie C, Tucci J, Franklin R, Anderson K. \u201cA lot of people call it liquid handcuffs\u201d \u2013 barriers and enablers to opioid replacement therapy in a rural area. J Subst Use. 2019;24:150\u20135.","journal-title":"J Subst Use"},{"key":"1302_CR36","unstructured":"British Columbia Centre on Substance Use. A Guideline for the Clinical Management of Opioid Use Disorder [Internet]. Opioid Use Disorder. 2023 [cited 2024 Oct 10]. Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf"},{"key":"1302_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/jrh.12264","volume":"34","author":"J Fonseca","year":"2018","unstructured":"Fonseca J, Chang A, Chang F. Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in southwestern Ontario. J Rural Health. 2018;34:23\u201330.","journal-title":"J Rural Health"},{"key":"1302_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2501\/JAR-2015-006","volume":"55","author":"S Gittelman","year":"2015","unstructured":"Gittelman S, Lange V, Cook WA, Frede SM, Lavrakas PJ, Pierce C, et al. Accounting for social-desirability bias in survey sampling: a model for predicting and calibrating the direction and magnitude of social-desirability bias. J Advert Res. 2015;55:242\u201354.","journal-title":"J Advert Res"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01302-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:01:14Z","timestamp":1759921274000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01302-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01302-z","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved through the University of British Columbia\/Providence Health Care Research Ethics Board. Written informed consent was provided by each participant prior to participating in the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent regarding using participant data in publication was provided by each participant in this study prior to the completion of each interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}